Liver Diseases Therapeutics Market Analysis and Forecast by Size, Share, Growth, Trends 2031
Coverage: Liver Diseases Therapeutics Market covers analysis by Type of Treatment (Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressant, Immunoglobulin's, Corticosteroids); End user (Hospitals, Adult Liver Disease Treatment Center, Ambulatory Surgical Center), and Geography (North America, Europe, Asia Pacific, and South and Central America)
- Report Date : Oct 2025
- Report Code : TIPRE00004580
- Category : Life Sciences
- Status : Upcoming
- Available Report Formats :
- No. of Pages : 150
The Liver Diseases Therapeutics Market is expected to register a CAGR of XX% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The report is categorized by Type of Treatment (Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressant, Immunoglobulin,s, Corticosteroids) and further analyzes the market based on End user (Hospitals, Adult Liver Disease Treatment Center, Ambulatory Surgical Center). A comprehensive breakdown is provided at global, regional, and country levels for each of these key segments.
The report includes market size and forecasts across all segments, presenting values in USD. It also delivers key statistics on the current market status of leading players, along with insights into prevailing market trends and emerging opportunities.
The report Liver Diseases Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Liver Diseases Therapeutics Market Segmentation
Type of Treatment- Antiviral Drugs
- Vaccines
- Chemotherapy
- Targeted Therapy
- Immunosuppressant
- Immunoglobulin
- s
- Corticosteroids
- Hospitals
- Adult Liver Disease Treatment Center
- Ambulatory Surgical Center
Strategic Insights
Liver Diseases Therapeutics Market Growth Drivers- Innovative Treatments Transforming Liver Disease Management
- Personalized Medicine Enhancing Patient Outcomes in Liver Care
- Rising Awareness Boosting Early Detection and Treatment Options
- AI-Powered Personalized Treatments Revolutionize Liver Disease Care
- Telehealth Expands Access to Liver Disease Management Globally
- Innovative Gene Therapies Show Promise in Liver Disease Reversal
- Revolutionizing Liver Care: Innovative Therapies on the Rise
- Personalized Treatments for Liver Diseases: A New Era of Healing
- Expanding Access: Affordable Liver Disease Solutions for All Patients
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Liver Diseases Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Liver Diseases Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liver Diseases Therapeutics Market - By Type of Treatment
1.3.2 Liver Diseases Therapeutics Market - By End user
1.3.3 Liver Diseases Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LIVER DISEASES THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LIVER DISEASES THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. LIVER DISEASES THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. LIVER DISEASES THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. LIVER DISEASES THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LIVER DISEASES THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE OF TREATMENT
7.1. OVERVIEW
7.2. TYPE OF TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. ANTIVIRAL DRUGS
7.3.1. Overview
7.3.2. Antiviral Drugs Market Forecast and Analysis
7.4. VACCINES
7.4.1. Overview
7.4.2. Vaccines Market Forecast and Analysis
7.5. CHEMOTHERAPY
7.5.1. Overview
7.5.2. Chemotherapy Market Forecast and Analysis
7.6. TARGETED THERAPY
7.6.1. Overview
7.6.2. Targeted Therapy Market Forecast and Analysis
7.7. IMMUNOSUPPRESSANT
7.7.1. Overview
7.7.2. Immunosuppressant Market Forecast and Analysis
7.8. IMMUNOGLOBULINS
7.8.1. Overview
7.8.2. Immunoglobulins Market Forecast and Analysis
7.9. CORTICOSTEROIDS
7.9.1. Overview
7.9.2. Corticosteroids Market Forecast and Analysis
8. LIVER DISEASES THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. ADULT LIVER DISEASE TREATMENT CENTER
8.4.1. Overview
8.4.2. Adult Liver Disease Treatment Center Market Forecast and Analysis
8.5. AMBULATORY SURGICAL CENTER
8.5.1. Overview
8.5.2. Ambulatory Surgical Center Market Forecast and Analysis
9. LIVER DISEASES THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Liver Diseases Therapeutics Market Overview
9.1.2 North America Liver Diseases Therapeutics Market Forecasts and Analysis
9.1.3 North America Liver Diseases Therapeutics Market Forecasts and Analysis - By Type of Treatment
9.1.4 North America Liver Diseases Therapeutics Market Forecasts and Analysis - By End user
9.1.5 North America Liver Diseases Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Liver Diseases Therapeutics Market
9.1.5.1.1 United States Liver Diseases Therapeutics Market by Type of Treatment
9.1.5.1.2 United States Liver Diseases Therapeutics Market by End user
9.1.5.2 Canada Liver Diseases Therapeutics Market
9.1.5.2.1 Canada Liver Diseases Therapeutics Market by Type of Treatment
9.1.5.2.2 Canada Liver Diseases Therapeutics Market by End user
9.1.5.3 Mexico Liver Diseases Therapeutics Market
9.1.5.3.1 Mexico Liver Diseases Therapeutics Market by Type of Treatment
9.1.5.3.2 Mexico Liver Diseases Therapeutics Market by End user
9.2. EUROPE
9.2.1 Europe Liver Diseases Therapeutics Market Overview
9.2.2 Europe Liver Diseases Therapeutics Market Forecasts and Analysis
9.2.3 Europe Liver Diseases Therapeutics Market Forecasts and Analysis - By Type of Treatment
9.2.4 Europe Liver Diseases Therapeutics Market Forecasts and Analysis - By End user
9.2.5 Europe Liver Diseases Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Liver Diseases Therapeutics Market
9.2.5.1.1 Germany Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.1.2 Germany Liver Diseases Therapeutics Market by End user
9.2.5.2 France Liver Diseases Therapeutics Market
9.2.5.2.1 France Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.2.2 France Liver Diseases Therapeutics Market by End user
9.2.5.3 Italy Liver Diseases Therapeutics Market
9.2.5.3.1 Italy Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.3.2 Italy Liver Diseases Therapeutics Market by End user
9.2.5.4 Spain Liver Diseases Therapeutics Market
9.2.5.4.1 Spain Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.4.2 Spain Liver Diseases Therapeutics Market by End user
9.2.5.5 United Kingdom Liver Diseases Therapeutics Market
9.2.5.5.1 United Kingdom Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.5.2 United Kingdom Liver Diseases Therapeutics Market by End user
9.2.5.6 Rest of Europe Liver Diseases Therapeutics Market
9.2.5.6.1 Rest of Europe Liver Diseases Therapeutics Market by Type of Treatment
9.2.5.6.2 Rest of Europe Liver Diseases Therapeutics Market by End user
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Liver Diseases Therapeutics Market Overview
9.3.2 Asia-Pacific Liver Diseases Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Liver Diseases Therapeutics Market Forecasts and Analysis - By Type of Treatment
9.3.4 Asia-Pacific Liver Diseases Therapeutics Market Forecasts and Analysis - By End user
9.3.5 Asia-Pacific Liver Diseases Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Liver Diseases Therapeutics Market
9.3.5.1.1 Australia Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.1.2 Australia Liver Diseases Therapeutics Market by End user
9.3.5.2 China Liver Diseases Therapeutics Market
9.3.5.2.1 China Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.2.2 China Liver Diseases Therapeutics Market by End user
9.3.5.3 India Liver Diseases Therapeutics Market
9.3.5.3.1 India Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.3.2 India Liver Diseases Therapeutics Market by End user
9.3.5.4 Japan Liver Diseases Therapeutics Market
9.3.5.4.1 Japan Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.4.2 Japan Liver Diseases Therapeutics Market by End user
9.3.5.5 South Korea Liver Diseases Therapeutics Market
9.3.5.5.1 South Korea Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.5.2 South Korea Liver Diseases Therapeutics Market by End user
9.3.5.6 Rest of Asia-Pacific Liver Diseases Therapeutics Market
9.3.5.6.1 Rest of Asia-Pacific Liver Diseases Therapeutics Market by Type of Treatment
9.3.5.6.2 Rest of Asia-Pacific Liver Diseases Therapeutics Market by End user
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Liver Diseases Therapeutics Market Overview
9.4.2 Middle East and Africa Liver Diseases Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Liver Diseases Therapeutics Market Forecasts and Analysis - By Type of Treatment
9.4.4 Middle East and Africa Liver Diseases Therapeutics Market Forecasts and Analysis - By End user
9.4.5 Middle East and Africa Liver Diseases Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Liver Diseases Therapeutics Market
9.4.5.1.1 South Africa Liver Diseases Therapeutics Market by Type of Treatment
9.4.5.1.2 South Africa Liver Diseases Therapeutics Market by End user
9.4.5.2 Saudi Arabia Liver Diseases Therapeutics Market
9.4.5.2.1 Saudi Arabia Liver Diseases Therapeutics Market by Type of Treatment
9.4.5.2.2 Saudi Arabia Liver Diseases Therapeutics Market by End user
9.4.5.3 U.A.E Liver Diseases Therapeutics Market
9.4.5.3.1 U.A.E Liver Diseases Therapeutics Market by Type of Treatment
9.4.5.3.2 U.A.E Liver Diseases Therapeutics Market by End user
9.4.5.4 Rest of Middle East and Africa Liver Diseases Therapeutics Market
9.4.5.4.1 Rest of Middle East and Africa Liver Diseases Therapeutics Market by Type of Treatment
9.4.5.4.2 Rest of Middle East and Africa Liver Diseases Therapeutics Market by End user
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Liver Diseases Therapeutics Market Overview
9.5.2 South and Central America Liver Diseases Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Liver Diseases Therapeutics Market Forecasts and Analysis - By Type of Treatment
9.5.4 South and Central America Liver Diseases Therapeutics Market Forecasts and Analysis - By End user
9.5.5 South and Central America Liver Diseases Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Liver Diseases Therapeutics Market
9.5.5.1.1 Brazil Liver Diseases Therapeutics Market by Type of Treatment
9.5.5.1.2 Brazil Liver Diseases Therapeutics Market by End user
9.5.5.2 Argentina Liver Diseases Therapeutics Market
9.5.5.2.1 Argentina Liver Diseases Therapeutics Market by Type of Treatment
9.5.5.2.2 Argentina Liver Diseases Therapeutics Market by End user
9.5.5.3 Rest of South and Central America Liver Diseases Therapeutics Market
9.5.5.3.1 Rest of South and Central America Liver Diseases Therapeutics Market by Type of Treatment
9.5.5.3.2 Rest of South and Central America Liver Diseases Therapeutics Market by End user
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LIVER DISEASES THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT LABORATORIES
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTELLAS PHARMA INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BRISTOL-MAYERS SQUIBB
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GILEAD SCIENCES
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. F. HOFFMANN-LA ROCHE LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SANOFI S.A.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Abbott Laboratories
2. Astellas Pharma Inc.
3. Bristol-Mayers Squibb
4. Gilead Sciences
5. GlaxoSmithKline plc.
6. F. Hoffmann-La Roche Ltd.
7. Merck and Co., Inc.
8. Novartis AG
9. Sanofi S. A.
10. Pfizer Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For